(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment for its global phase three 'Saffron' trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients with MET overexpression or amplification who had progressed following Tagrisso treatment.
The AIM-traded firm said...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE